Zydus gets US nod for schizophrenia generic medicine

Zydus Lifesciences has received the USFDA's final approval to produce a generic version of Paliperidone extended-release tablets, which are used to treat schizophrenia and schizoaffective disorders. The approval covers strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg, with production set at the SEZ facility in Ahmedabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DfHrg9w
via IFTTT